{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:00:12Z","timestamp":1792699212807,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.semradonc.2021.02.008","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T19:08:57Z","timestamp":1630004937000},"page":"361-370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Immunotherapy for HPV Malignancies"],"prefix":"10.1016","volume":"31","author":[{"given":"Maxwell Y.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint T.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semradonc.2021.02.008_bib0001","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/214992a0","article-title":"Cellular basis of the immunological defects in thymectomized mice","volume":"214","author":"Miller","year":"1967","journal-title":"Nature"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0002","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0003","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0004","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0005","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1186\/s12885-019-6388-4","article-title":"High risk HPV infection prevalence and associated cofactors: a population-based study in female ISSSTE beneficiaries attending the HPV screening and early detection of cervical cancer program","volume":"19","author":"Torres-Poveda","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0006","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.vaccine.2019.03.052","article-title":"Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix\u00ae or Gardasil\u00ae vaccine","volume":"37","author":"Godi","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0007","doi-asserted-by":"crossref","first-page":"29608","DOI":"10.1074\/jbc.M110.126722","article-title":"A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers","volume":"285","author":"Riemer","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0008","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1158\/1078-0432.CCR-14-3341","article-title":"Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6","volume":"21","author":"Draper","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0009","first-page":"5420","article-title":"Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6","volume":"167","author":"Evans","year":"2001","journal-title":"J Immunol Baltim Md 1950"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.99488","article-title":"Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model","volume":"3","author":"Jin","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0011","first-page":"5934","article-title":"Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides","volume":"154","author":"Ressing","year":"1995","journal-title":"J Immunol Baltim Md 1950"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0012","first-page":"582","article-title":"Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope","volume":"56","author":"Ressing","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0013","first-page":"2929","article-title":"A tumor suppressor gene, Cx26, also mediates the bystander effect in HeLa cells","volume":"57","author":"Mesnil","year":"1997","journal-title":"Cancer Res"},{"issue":"Pt 7","key":"10.1016\/j.semradonc.2021.02.008_bib0014","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1099\/0022-1317-78-7-1689","article-title":"Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide","volume":"78","author":"Jochmus","year":"1997","journal-title":"J Gen Virol"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0015","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1158\/1055-9965.EPI-11-0734","article-title":"Risk Factors for Oral HPV Infection among a High Prevalence Population of HIV-Positive and At-Risk HIV-Negative Adults","volume":"21","author":"Beachler","year":"2012","journal-title":"Cancer Epidemiol Prev Biomark"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0016","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/jnci\/95.14.1062","article-title":"Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women","volume":"95","author":"Strickler","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0017","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0304-3835(01)00871-0","article-title":"Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo","volume":"179","author":"Um","year":"2002","journal-title":"Cancer Lett"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0018","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.oraloncology.2013.09.010","article-title":"Tailored immunotherapy for HPV positive head and neck squamous cell cancer","volume":"50","author":"Gildener-Leapman","year":"2014","journal-title":"Oral Oncol"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0019","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1002\/ijc.22089","article-title":"E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain","volume":"119","author":"Ashrafi","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0020","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0021","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0022","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0023","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0024","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1126\/science.aak9510","article-title":"Landscape of immunogenic tumor antigens in successful immunotherapy of virally-induced epithelial cancer","volume":"356","author":"Stevanovi\u0107","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0025","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3892\/mmr.2017.6102","article-title":"Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity","volume":"15","author":"Liu","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0026","doi-asserted-by":"crossref","first-page":"13404","DOI":"10.1038\/s41598-019-49771-0","article-title":"HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0027","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1158\/0008-5472.CAN-12-2606","article-title":"PD-1\u2013Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer","volume":"73","author":"Badoual","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0028","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0029","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2018.11.015","article-title":"Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with \u226525% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy","volume":"107","author":"Zandberg","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0031","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0032","first-page":"ix89","article-title":"KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer","volume":"30","author":"Fujiwara","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semradonc.2021.02.008_bib0033","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS6096","article-title":"ENGOT-cx11\/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer","volume":"38","author":"Lorusso","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0034","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0035","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0036","doi-asserted-by":"crossref","first-page":"852","DOI":"10.6004\/jnccn.2018.0060","article-title":"Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Benson","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2","volume":"10","author":"Lan","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0038","doi-asserted-by":"crossref","first-page":"6833","DOI":"10.1158\/0008-5472.CAN-14-0602-T","article-title":"TGF\u03b2 receptor 1: an immune susceptibility gene in HPV-associated cancer","volume":"74","author":"Levovitz","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0039","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-CT075","article-title":"Abstract CT075: Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies","volume":"79","author":"Strauss","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0040","first-page":"6132","article-title":"Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes","volume":"59","author":"Klaes","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3802\/jgo.2016.27.e51","article-title":"Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research","volume":"27","author":"Lee","year":"2016","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0042","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev-immunol-032712-095910","article-title":"Pathways of Antigen Processing","volume":"31","author":"Blum","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0043","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1158\/1078-0432.CCR-17-2140","article-title":"Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer","volume":"24","author":"Welters","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0044","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-04-0831","article-title":"Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6","volume":"64","author":"Jong","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0045","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.5306\/wjco.v5.i5.1002","article-title":"Immune therapy for human papillomaviruses-related cancers","volume":"5","author":"Rosales","year":"2014","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0046","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/14712598.8.4.421","article-title":"Therapeutic human papillomavirus vaccines: current clinical trials and future directions","volume":"8","author":"Hung","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0047","doi-asserted-by":"crossref","first-page":"9184","DOI":"10.1074\/jbc.M809456200","article-title":"Comparing Pooled Peptides with Intact Protein for Accessing Cross-presentation Pathways for Protective CD8+ and CD4+ T Cells","volume":"284","author":"Zhang","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0048","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0049","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0050","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1158\/1078-0432.CCR-15-2594","article-title":"Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar\/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response","volume":"22","author":"van Poelgeest","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0051","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/1078-0432.CCR-07-1881","article-title":"Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity","volume":"14","author":"Kenter","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0052","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16\u2013Related Cancer: A Phase 2 Clinical Trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0053","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1158\/0008-5472.CAN-16-0881","article-title":"Tumor Eradication by Cisplatin Is Sustained by CD80\/86-Mediated Costimulation of CD8+ T Cells","volume":"76","author":"Nejad","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0054","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aaz8235","article-title":"Strong vaccine responses during chemotherapy are associated with prolonged cancer survival","volume":"12","author":"Melief","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0055","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.vaccine.2003.07.003","article-title":"Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes","volume":"22","author":"Cassetti","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0056","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1586\/14760584.2016.1157477","article-title":"Current State in the Development of Candidate Therapeutic HPV Vaccines","volume":"15","author":"Yang","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0057","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.gt.3302252","article-title":"Comparison of HPV DNA vaccines employing intracellular targeting strategies","volume":"11","author":"Kim","year":"2004","journal-title":"Gene Ther"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0058","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1084\/jem.188.6.1075","article-title":"Predominant Role for Directly Transfected Dendritic Cells in Antigen Presentation to CD8+ T Cells after Gene Gun Immunization","volume":"188","author":"Porgador","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0059","first-page":"2850","article-title":"Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice","volume":"165","author":"Dupuis","year":"2000","journal-title":"J Immunol Baltim Md 1950"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0060","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-18-1763","article-title":"Immunotherapy Targeting HPV16\/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer","volume":"25","author":"Aggarwal","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0061","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004414","article-title":"Immunotherapy Against HPV16\/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses","volume":"4","author":"Bagarazzi","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0062","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0063","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.204.Supp.91.6","article-title":"Anti-tumor efficacy and immune responses induced by a novel therapeutic HPV-specific gorilla adenovirus off-the-shelf immunotherapeutic (PRGN-2009)","volume":"204","author":"Pellom","year":"2020","journal-title":"J Immunol"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0064","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40661-017-0046-9","article-title":"Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy","volume":"4","author":"Miles","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0065","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/IGC.0000000000001235","article-title":"A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes\u2013Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer","volume":"28","author":"Basu","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0066","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ijrobp.2018.01.004","article-title":"Tolerability of ADXS11-001 Lm-LLO Listeria-Based Immunotherapy With Mitomycin, Fluorouracil, and Radiation for Anal Cancer","volume":"100","author":"Safran","year":"2018","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0067","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.gt.3301160","article-title":"Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity","volume":"7","author":"Wang","year":"2000","journal-title":"Gene Ther"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0068","first-page":"1184","article-title":"Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6\/E7 fusion protein and autologous dendritic cells","volume":"59","author":"Murakami","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0069","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1479-5876-6-21","article-title":"Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells","volume":"6","author":"Benencia","year":"2008","journal-title":"J Transl Med"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0070","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1128\/JVI.02343-07","article-title":"Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial","volume":"82","author":"Santin","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0071","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1126\/science.8097338","article-title":"Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages","volume":"260","author":"Hsieh","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0072","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00262-014-1640-x","article-title":"A Phase I Dose Escalation Trial of MAGE-A3 and HPV16 Specific Peptide Immunomodulatory Vaccines in Patients with Recurrent \/Metastatic (RM) Squamous Cell Carcinoma of the Head and Neck (SCCHN)","volume":"64","author":"Zandberg","year":"2015","journal-title":"Cancer Immunol Immunother CII"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0073","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4161\/hv.4.4.5742","article-title":"Improving vaccine delivery using novel adjuvant systems","volume":"4","author":"Pichichero","year":"2008","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0074","doi-asserted-by":"crossref","first-page":"403","DOI":"10.18632\/oncotarget.1719","article-title":"Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing","volume":"5","author":"Gameiro","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0075","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1172\/JCI200112346","article-title":"Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen","volume":"108","author":"Cheng","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0076","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13578-015-0025-y","article-title":"Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination","volume":"5","author":"Yang","year":"2015","journal-title":"Cell Biosci"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0077","first-page":"493","article-title":"A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+ T-cell immune response","volume":"11","author":"Kim","year":"2004","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0078","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/mt.2015.120","article-title":"Ubiquitin-like Molecule ISG15 Acts as an Immune Adjuvant to Enhance Antigen-specific CD8 T-cell Tumor Immunity","volume":"23","author":"Villarreal","year":"2015","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0079","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.cgt.7700723","article-title":"DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins","volume":"11","author":"Wlazlo","year":"2004","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0080","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0264-410X(99)00528-9","article-title":"Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines","volume":"18","author":"Chen","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0081","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1525-0016(03)00238-7","article-title":"Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles","volume":"8","author":"Lin","year":"2003","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0082","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-005-0700-7","article-title":"Prime\/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara","volume":"55","author":"Mackova","year":"2006","journal-title":"Cancer Immunol Immunother CII"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0083","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/1078-0432.CCR-13-1334","article-title":"Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors","volume":"20","author":"Wu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0084","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00262-013-1421-y","article-title":"Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects","volume":"62","author":"Lee","year":"2013","journal-title":"Cancer Immunol Immunother CII"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0085","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00262-012-1322-5","article-title":"Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine","volume":"62","author":"Peng","year":"2013","journal-title":"Cancer Immunol Immunother CII"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0086","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1158\/1078-0432.CCR-08-0116","article-title":"Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines","volume":"14","author":"Smith","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0087","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","article-title":"A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone","volume":"316","author":"Rosenberg","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0088","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0089","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0090","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus\u2013Targeted Tumor-Infiltrating T Cells","volume":"33","author":"Stevanovi\u0107","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0091","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus\u2013associated Epithelial Cancers","volume":"25","author":"Stevanovi\u0107","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0092","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/imr.12132","article-title":"Exploiting the curative potential of adoptive T-cell therapy for cancer","volume":"257","author":"Hinrichs","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0093","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-Cell Receptor Gene Therapy for Human Papillomavirus\u2013Associated Epithelial Cancers: A First-in-Human, Phase I\/II Study","volume":"37","author":"Doran","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0094","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2018-99-117017","article-title":"Regression of Epithelial Cancers Following T Cell Receptor Gene Therapy Targeting Human Papillomavirus-16 E7","volume":"132","author":"Norberg","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0095","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0096","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0097","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0098","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1158\/1078-0432.CCR-14-1138","article-title":"Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response","volume":"20","author":"Kuo","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0099","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/hed.23535","article-title":"Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer","volume":"36","author":"Campian","year":"2014","journal-title":"Head Neck"},{"key":"10.1016\/j.semradonc.2021.02.008_bib0100","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/hed.25101","article-title":"Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer","volume":"40","author":"Morisada","year":"2018","journal-title":"Head Neck"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429621000163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429621000163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:52:30Z","timestamp":1760950350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429621000163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1053429621000163"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2021.02.008","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy for HPV Malignancies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2021.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}